(Solid Tumors) Is Keytruda Effective?
(Solid Tumors) Is Keytruda Effective?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
(Solid Tumors) Is Keytruda Effective?
- February 3, 2023
- Read time: 1 minute
On January 9, 2023, Kaysia Ludford and colleagues from The University of Texas MD Anderson Cancer Center published results of a Phase 2 clinical trial (NCT04082572) in the Journal of Clinical Oncology, evaluating the efficacy and safety of Keytruda as neoadjuvant therapy in patients with advanced metastatic solid tumors with MSI-High and dMMR status.
This Phase 2 clinical trial was conducted as an open-label trial at independent facilities, administering Keytruda (600mg per 3-week cycle, maximum 6 months treatment duration) as neoadjuvant therapy to patients with advanced metastatic solid tumors with MSI-High and dMMR status. Following surgery, patients continued treatment for up to one year based on individual choice. The primary endpoints were pathologic complete response rate and safety, while secondary endpoints included organ preservation rate in patients not undergoing surgery.
Results from 35 enrolled patients (27 with colorectal cancer, 8 with non-colorectal cancer) were as follows: among 33 patients evaluable for efficacy, the objective response rate was 82%, and the primary endpoint of pathologic complete response rate (in 17 patients who underwent surgery) was 65%.
Regarding safety, no new adverse events were identified in this trial, consistent with the current safety profile of Keytruda from other clinical trials.
Based on Phase 2 clinical trial results, Kaysia Ludford and colleagues concluded: Patients with advanced metastatic solid tumors with MSI-High and dMMR status treated with Keytruda as neoadjuvant therapy demonstrated good tolerability to adverse events and favorable pathologic complete response rates, offering patients an organ-preservation option.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.22.01351?journalCode=jco
-
Clinical Trial Medications
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase 2 Trial Results. (Lung Cancer) HER2-Mutated Non-Small Cell Lung Cancer with Enhertu Effective? (Lung Cancer) Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4